Little is known about the fundamental causes of bronchial asthma and the alterations in pulmonary physiology leading to an attack. The abnormal reaction of the tracheobronchial tree to histamine and to cholinergic substances such as methacholine and pilocarpine has been studied in detail (1) (2) (3) . The parenteral administration of these drugs brings about a sharp reduction in maximum minute ventilation and vital capacity associated with an evanescent asthma-like attack. The intensity of the pulmonary reaction appears to be associated with the degree of asthma (4) , and may be modified by various anti-asthmatic agents such as epinephrine, Orthoxine, aminophylline, Benadryl, Pyrrolazote and hyoscyamine (5) . A relationship also exists between the clinical effectiveness of anti-asthmatic agents and the degree of protection they afford against the pulmonary response to injected methacholine and histamine (6) .
It is not clear why the tracheobronchial tree in asthmatic subjects reacts in an abnormal manner. It is not likely that infection of the mucous membranes in the lungs is the sole cause since some of our reactive subjects had not had an attack of asthma in over 20 years, and some had no history of bronchitis or other pulmonary infection. Moreover, in a few subjects with hay fever who had never suffered with asthma, the injection of methacholine produced a notable reduction in vital capacity (2) . The clinical improvement reported in some patients after surgical interruption of the para-sympathetic and sympathetic pathways of. the lungs (7, 8) suggests that a reflex mechanism may be involved. Further support of this idea is furnished by studies carried out in conjunction with Dr. George Whitelaw in which bilateral procaine block of stellate ganglia modified the pulmonary response to methacholine and histamine (9) . It was felt worthwhile, therefore, to observe the effect of a sympatholytic drug in similar studies.
Dihydroergocornine, a dihydrogenated alkaloid of ergot, was chosen because it is relatively nontoxic, short-acting and may be administered by mouth as well as by vein (10) .
MATERIAL AND METHODS
The method of study has been reported elsewhere in detail (1, 6 where Dc = control decrease in vital capacity after methacoline or histamine, before administration of dihydroergocornine. Vc = control vital capacity before methacholine or histamine, and before administration of dihydroergocornine. Dt = decrease in vital capacity after methacholine or histamine during the particular test. and P = per cent protection. A similar formula was used for the maximum ventilatory studies. The degree of protection probably should exceed 50 per cent in order to be significant.
RESULTS AND COMMENTS
Dihydroergocornine was given intravenously to 12 subjects with bronchial asthma; in 10, protection studies against methacholine were performed, and in four, similar studies with histamine, (Tables  I, II 
injection of 2 mg. of methacholine resulted in only a slight decrease in both measurements and no subjective sensation in the chest. A third intramuscular injection of 2 mg. of methacholine, 30 minutes after the dihydroergocornine, likewise produced little effect. Thus, in this subject complete protection was afforded by dihydroergocornine from the subjective effects of methacholine, and almost complete protection against the reduction in vital capacity and maximum minute ventilation previously produced by the drug. In at least six cases the results were significant, in that over 50 per cent protection was achieved with both measurements of pulmonary function. In four studies with histamine, protection varied from zero to 78 per cent with both maximum minute ventilation and vital capacity studies, and in two cases the degree of protection was significant.
Why dihydroergocornine affords protection against the action of methacholine and histamine in the tracheobronchial tree is not clear. The drug apparently does not have any notable direct anticholinergic or antihistamine action. It seems possible that the response to methacholine in the lung of asthmatic subjects may be the result of a twostage reaction. It is postulated that the first component of the reaction is a direct response of the lung to the compound. This varies with the degree of asthma and may depend in part on the presence of infection in the lung. The second component may be a reflex bronchoconstriction set up by the initial reaction of methacholine. It is suggested that this reflex is non-specific and may be set off by various types of stimuli, such as hyperventilation, irritant gases, laughing and sneezing, in addition to methacholine and histamine. The afferent or efferent limbs of the reflex might well be over the sympathetic pathways in the lungs. Thus, procaine block or surgical interruption of these pathways, or the administration of dihydroergocornine would abolish the reflex component of the methacholine reaction without affecting the direct response of the tracheobronchial tree to the drug. Thus protection afforded by dihydroergocornine against drug-induced attacks of asthma is variable and usually not complete. Similarly, in spontaneous bronchial asthma, sympathetic resection may bring about varying degrees of relief depending perhaps on the importance of the reflex component in each case of asthma. The demonstration of protection following dihydroergocornine may, therefore, indicate those cases in which sympathectomy may be of greatest benefit to the patient. The drug may also be useful in controlling spontaneous bronchial asthma. The occurrence of protection against methacholine in subject R. G. after aerosolization of dihydroergocornine suggests that further studies of adrenergic blocking agents by this route of administration should be carried out.
SUM MARY
Dihydroergocornine in intravenous doses of from 0.25 to 0.75 mg. was administered to a group of 12 subjects with bronchial asthma. Protective tests were performed by measuring the change in the vital capacity and maximum minute ventilation, due to histamine and methacholine before and after the administration of dihydroergocornine.
In eight cases protection of 50 per cent or more resulted and no serious side reactions were experienced. The results suggest an explanation for the hyper-responsiveness of the tracheobronchial tree to histamine and cholinergic drugs in asthmatic subjects. The clinical implications are discussed. 
